Immupharma (IMM)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

2.70p
   
  • Change Today:
    -0.040p
  • 52 Week High: 5.90
  • 52 Week Low: 1.09
  • Currency: UK Pounds
  • Shares Issued: 499.72m
  • Volume: 1,849,652
  • Market Cap: £13.49m
  • RiskGrade: 328

Growth Ratings

EPS Growth shows the relative growth of a company's earnings over the last year.

The rise in total monies receivable for goods / services sold before expenses.

1yr EPS Growth Not Available
1yr Revenue Growth Not Available

Income Ratings

The percentage of the share price that a company pays out as dividends over a year.

The percentage change from the previous year in the dividend paid on each share.

Dividend Yield Not Available
1yr DPS Growth Not Available

Valuation Ratings

The share price as a ratio of revenue per share.

The share price as a ratio of net asset value.

Price Sales Ratio Not Available
Price Book Ratio Not Available

Performance Ratings

In percentage total change in share price over 30 days.

In percentage total change in share price over 3 months.

Price Chg 30d
8.84% below the market average8.84% below the market average8.84% below the market average8.84% below the market average8.84% below the market average
27.66% below the sector average27.66% below the sector average27.66% below the sector average27.66% below the sector average27.66% below the sector average
Price Chg 3m
81.01% below the market average81.01% below the market average81.01% below the market average81.01% below the market average81.01% below the market average
65.96% below the sector average65.96% below the sector average65.96% below the sector average65.96% below the sector average65.96% below the sector average

Technical Ratings

The Relative Strength Index measures a share price relative to itself and its recent history.

Momentum is an oscillator that measures the rate of price change.

RSI
23.23% below the market average23.23% below the market average23.23% below the market average23.23% below the market average23.23% below the market average
25.58% below the sector average25.58% below the sector average25.58% below the sector average25.58% below the sector average25.58% below the sector average
Momentum 20
26.73% below the market average26.73% below the market average26.73% below the market average26.73% below the market average26.73% below the market average
16.28% below the sector average16.28% below the sector average16.28% below the sector average16.28% below the sector average16.28% below the sector average

Management Ratings

Operating Margin is profit as a percentage of sales.

Return on capital employed measures the return from invested and borrowed capital.

Operating Margin Not Available
ROCE
94.57% above the market average94.57% above the market average94.57% above the market average94.57% above the market average94.57% above the market average
71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average

Profitability Ratings

Earnings per share, the company's profitability expressed on a per share basis.

Analysts' estimates of future EPS for the next 2 years.

EPS
47.52% below the market average47.52% below the market average47.52% below the market average47.52% below the market average47.52% below the market average
14.89% above the sector average14.89% above the sector average14.89% above the sector average14.89% above the sector average14.89% above the sector average
Forecast EPS Not Available

Profit/Loss Ratings

Monies produced from sales of goods and services after trade discounts, VAT, etc.

Operating Profit is the profit after deducting operating costs from gross profits.

Turnover Not Available
Operating Profit Loss
61.94% below the market average61.94% below the market average61.94% below the market average61.94% below the market average61.94% below the market average
6.38% above the sector average6.38% above the sector average6.38% above the sector average6.38% above the sector average6.38% above the sector average

Balance Sheet Ratings

The difference between current assets and current liabilities.

A current asset representing the company's financial liquidity.

Assets
83.99% below the market average83.99% below the market average83.99% below the market average83.99% below the market average83.99% below the market average
69.57% below the sector average69.57% below the sector average69.57% below the sector average69.57% below the sector average69.57% below the sector average
Cash
81.16% below the market average81.16% below the market average81.16% below the market average81.16% below the market average81.16% below the market average
82.61% below the sector average82.61% below the sector average82.61% below the sector average82.61% below the sector average82.61% below the sector average

Director Deal Ratings

The cumulative amount of stocks sold by company directors over 1 year

The cumulative amount of stocks bought by company directors over 1 year

Sells 1y Not Available
Buys 1y Not Available

Broker Ratings

The percentage of stockbrokers that rate the company as a Buy

The percentage of stockbrokers that rate the company as a Hold

Brokers Percent Buy Not Available
Brokers Percent Neutral Not Available

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Immupharma Market Data

Currency UK Pounds
Share Price 2.70p
Change Today -0.040p
% Change -1.46 %
52 Week High 5.90
52 Week Low 1.09
Volume 1,849,652
Shares Issued 499.72m
Market Cap £13.49m
RiskGrade 328

Immupharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
28.7% below the market average28.7% below the market average28.7% below the market average28.7% below the market average28.7% below the market average
14.89% above the sector average14.89% above the sector average14.89% above the sector average14.89% above the sector average14.89% above the sector average
Price Trend
65.50% above the market average65.50% above the market average65.50% above the market average65.50% above the market average65.50% above the market average
87.23% above the sector average87.23% above the sector average87.23% above the sector average87.23% above the sector average87.23% above the sector average
Income Not Available
Growth Not Available

Immupharma Dividends

No dividends found

Trades for 28-May-2025

Time Volume / Share Price
16:28 132 @ 2.65p
15:50 110,000 @ 2.67p
15:07 20,000 @ 2.67p
15:01 3,619 @ 2.76p
14:57 100,000 @ 2.70p

Immupharma Key Personnel

CEO Timothy Paul McCarthy

Top of Page